initi buy pt hard
expect name investor seek gener exposur
initi coverag buy rate pt
start point see stock depress valuat financi
expect lower enough believ stock
outperform despit challeng environ base divers
global busi larg pipelin includ biosimilar addit recent
launch gadvair biosimilar neulasta gain traction
help creat visibl difficult fight investor percept
compani particularli sharehold friendli hope
on-going strateg review could help unlock valu manag
indic review near complet click initi
note pharmaceut stock
well-built global gener specialti busi
believ myl global busi vertic integr divers
product gener brand over-the-counter geographi us europ asia latam
 capabl posit compani well address macro challeng
expertis willing make signific invest order
bring challeng product market gadvair gcopaxon
compani one largest biosimilar pipelin industri
first market ftm us biosimilar neulasta fulphila believ
could ftm biosimilar herceptin ogivri
strateg review could lead value-cr initi
announc committe independ director form
conduct strateg review option unlock sharehold valu
outcom difficult predict manag note earn
call believ strateg review near complet believ
street low expect
us gener industri trend improv challeng persist
gener price pressur driven custom consolid seem
moder market particip note improv trend front
hand gener player note innov employ
aggress tactic rebat mitig gener penetr make
gener opportun less valuabl past
valuat risk
pt assum stock trade ebitda
support dcf analysi downsid risk includ increas
competit intens gener greater price pressur us europ
tr target
area delay approv quality/manufactur issu fine relat opioid litig
investig gener price collus disappoint capit deploy
page
develop manufactur market gener brand gener biosimilar brand
drug over-the-counter product countri myl north america busi primarili focus
gener drug europ row segment focus brand over-the-counter product
compani establish broad biosimilar portfolio collabor biocon
rate partner
model assumpt valuat
target price assum stock trade ebitda
ep refer stock histor trade averag multipl forward next
month ebitda ep respect
mean median high low base data
mean median high low base data
target support dcf analysi model sale period determin
termin valu base termin growth rate assumpt underli dcf analysi includ
north america return growth driven part gadvair full year contribut
fulphila biosimilar neulasta follow stabl sale contribut launch offset
base eros compound-annual-growth-rate
europ grow compound-annual-growth-rate
page
north sale sale
row grow compound-annual-growth-rate
gross margin remain stabl
assum termin growth rate discount after-tax profit back end
believ approxim compani weight averag cost capit
figur summar estim figur summar dcf analysi
page
changetot revenuegross
north america return growth
acceler driven new
launch compound-annual-growth-rate
europe/row grow
compound-annual-growth-rate
gross margin expand
driven part
gadvair full year
contribut fulphila
stabl sale contribut
launch offset base
eros compound-annual-growth-rate
europe/row grow
compound-annual-growth-rate
gross margin remain stabl
continu base eros offset
compound-annual-growth-rate
europe/row grow
compound-annual-growth-rate
gross margin erod
liabil relat opioid/oth
page
repres report sale
page
potenti gener launchestimingsal commentsgener note earn call receiv minor alreadi submit respons action date tad second half februari compani expect grestasi signific contributor due potenti number competitor insulin glargin expect fda approv insulin glargin biosimilar lantu biosimilar herceptin mileston eventstimingcommentsoutcom strateg announc committe independ director form conduct strateg review option unlock sharehold valu manag note earn call believ strateg review near complet fda action grestasi comment earn call receiv minor fda request minor clarif alreadi submit respons action date tad second half februari case state ok teva purdu schedul go su teva purdu june alleg fraudul market drug fuel opioid epidem ok ag seek unspecifi damag compani trial schedul begin involv case could shape sentiment potenti liabil relat opioid investor dayfal plan host investor day fall bellweth case opioid multi-district litig mdl oh schedul go trialoct judg overse opioid multi-district litig mdl usdc-northern district oh schedul bellweth trial begin octob yet clear compani involv trial updat morgantown warn receiv fda warn letter novemb relat inspect morgantown wv facil compani address issu rais warn letter facil continu suppli product us market forecast signific new product revenu facil anda pend approv repres annual brand sale per iqvia pend anda potenti first-to-fil ftf opportun repres annual brand sale per iqvia mylan
page
changetot
page
changetot
page
biosimilar north third parti third parti changenorth biosimilar neulasta gener advairtot north third parti third parti revenuenorth biosimilar north third parti third parti biosimilar gross biosimilar gross
page
biosimilar north third parti third parti changenorth biosimilar north third parti third parti revenuenorth biosimilar north third parti third parti biosimilar gross biosimilar gross
statement balanc sheet
page
statementgaap net oper work flow sale invest flow from/ repay issuanc stock common financ flow foreign exchang equival increas equival sheetcash current current tax tax current current tax stockhold liabil stockhold
statement balanc sheet cont
page
analysistot debt/adjust debt/adjust flow oper net cash flow
develop manufactur market gener brand gener biosimilar brand
drug over-the-counter product countri myl north america busi primarili focus
gener drug europ row segment focus brand over-the-counter product
compani establish broad biosimilar portfolio collabor biocon
start point see stock depress valuat financi expect
lower enough believ stock outperform despit
challeng environ base divers global busi larg pipelin includ biosimilar
addit recent launch gadvair biosimilar neulasta gain traction help
creat visibl difficult fight investor percept compani
particularli sharehold friendli hope on-going strateg review could help unlock
valu manag indic review near complet rate share buy
valuat risk
pt assum stock trade ebitda support
intens gener greater price pressur us europ area delay approv
quality/manufactur issu fine relat opioid litig investig gener price
collus disappoint capit deploy
compani mention note
biocon limit rate
gregg gilbert herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
